

Eporgen

Venture



Eporgen Venture is the first Italian company, entirely funded by private, non-institutional investors, which is dedicated to seed capital investments in the area of life sciences.

Eporgen's mission is to identify and select innovative projects in the area of life sciences, in which it invests in order to create a balanced portfolio of small start-up companies that are supported in their management and controlled by Eporgen. These start-up companies are built around intellectual property that is being developed up to a proof-of-concept stage and subsequently licensed out to suitable partners, to generate new economic resources.

The current portfolio of Eporgen is constituted of eleven start-up companies, with innovative early stage therapeutics and diagnostics that cover diverse disease areas (oncology, anti-infectives, cardiovascular), approaches (small molecules, proteins, peptides, vaccines) and technology applications.

Eporgen commenced operations in 2005 and is based in the "Silvano Fumero" Bioindustry Park, close to Ivrea in the Piedmont region of Italy.

Since its creation, Eporgen has experienced a steady growth and today has doubled its original portfolio to a total of 11 start-up companies with 19 patents, its investor base to a total of 70 investors and the amount of money raised to a total of €7.8m in four subsequent financing rounds. Eporgen has also successfully participated in a number of public Italian and European financing initiatives and has received to date over €1m in grants.

With about 30 staff in total, Eporgen and its start-up companies operate an efficient business model that combines aspects of a venture capital and a virtual pharma company and relies on a network of scientific advisors, contract research organisations and academic institutions.

About half the start-up companies in Eporgen's portfolio have reached or are about to reach proof-of-concept stage and are/will be seeking partnerships for further development of their technology.



nurturing the
winners





Management Team

Konstantinos Efthymiopoulos, CEO & President
Luciano Stabile, VP Administration and Finance
Lorenzo Boscarelli, VP Human Resources
Prof. Gianni Garotta, Scientific Director
Luciana Orlando, Director of Projects

PRODUCTS PORTFOLIO

		DISCOVERY	LEAD OPTIMIZATION	REGULATORY PRECLINICAL	CLINICAL PHASE I	
	Oncology					Peptides
	Oncology					Oligonucleotides
	Autoimmune diseases					Therapeutic vaccines
	Oncology					
	Oncology					Small molecules
	Neonatal infections					Neutraceuticals
	Anti-infectives					Peptides
	Cardiovascular					Recombinant proteins

TECHNOLOGIES PORTFOLIO

		DEVELOPMENT	VALIDATION	MARKET
	Eco-friendly anti-fouling paints			
	Single cell electroporation			
	Diagnosis and therapy of autoimmune diseases			
	Rapid and non-invasive test for early identification of dental caries			

Business Development

Eporgen is searching for suitable partners for collaborations and out-licensing of projects within its portfolio of start-up companies. To discuss potential opportunities, please contact us at the following e mail address: info@eporgen.com

Eporgen Venture S.p.A.
 c/o "Silvano Fumero" Bioindustry Park, Via Ribes 5, 10010 Colletterto Giacosa (TO), ITALY; Tel. +39 0125 561000; Fax +39 0125 538791